138 related articles for article (PubMed ID: 17489884)
1. Inherited long QT syndrome revealed by antifungals drug-drug interaction.
Eiden C; Peyrière H; Tichit R; Cociglio M; Amedro P; Blayac JP; Margueritte G; Hillaire-Buys D
J Clin Pharm Ther; 2007 Jun; 32(3):321-4. PubMed ID: 17489884
[TBL] [Abstract][Full Text] [Related]
2. OTc prolongation and torsade de pointes ventricular tachycardia in a small dose voriconazole therapy.
Elbey MA; Cil H; Onturk E; Islamoglu Y
Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):100-2. PubMed ID: 22338554
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole-induced QT interval prolongation and torsades de pointes.
Aypar E; Kendirli T; Tutar E; Çiftçi E; Ince E; Ileri T; Atalay S
Pediatr Int; 2011 Oct; 53(5):761-763. PubMed ID: 21955009
[No Abstract] [Full Text] [Related]
4. Torsades de pointes associated with voriconazole use.
Philips JA; Marty FM; Stone RM; Koplan BA; Katz JT; Baden LR
Transpl Infect Dis; 2007 Mar; 9(1):33-6. PubMed ID: 17313469
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.
Moriyama B; Jarosinski PF; Figg WD; Henning SA; Danner RL; Penzak SR; Wayne AS; Walsh TJ
Pharmacotherapy; 2013 Mar; 33(3):e19-22. PubMed ID: 23400848
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect.
Alkan Y; Haefeli WE; Burhenne J; Stein J; Yaniv I; Shalit I
Clin Infect Dis; 2004 Sep; 39(6):e49-52. PubMed ID: 15472801
[TBL] [Abstract][Full Text] [Related]
7. Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients.
Zeuli JD; Wilson JW; Estes LL
Antimicrob Agents Chemother; 2013 Mar; 57(3):1121-7. PubMed ID: 23229485
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
[TBL] [Abstract][Full Text] [Related]
9. Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype.
Geist MJ; Egerer G; Burhenne J; Mikus G
Antimicrob Agents Chemother; 2006 Sep; 50(9):3227-8. PubMed ID: 16940139
[No Abstract] [Full Text] [Related]
10. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
11. Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.
Moriyama B; Falade-Nwulia O; Leung J; Penzak SR; JJingo C; Huang X; Henning SA; Wilson WH; Walsh TJ
Mycoses; 2011 Nov; 54(6):e877-9. PubMed ID: 21615537
[TBL] [Abstract][Full Text] [Related]
12. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.
Fournier S; Pavageau W; Feuillhade M; Deplus S; Zagdanski AM; Verola O; Dombret H; Molina JM
Eur J Clin Microbiol Infect Dis; 2002 Dec; 21(12):892-6. PubMed ID: 12525928
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.
Driscoll TA; Frangoul H; Nemecek ER; Murphey DK; Yu LC; Blumer J; Krance RA; Baruch A; Liu P
Antimicrob Agents Chemother; 2011 Dec; 55(12):5780-9. PubMed ID: 21911570
[TBL] [Abstract][Full Text] [Related]
14. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.
Mok NS; Lo YK; Tsui PT; Lam CW
J Cardiovasc Electrophysiol; 2005 Dec; 16(12):1375-7. PubMed ID: 16403073
[TBL] [Abstract][Full Text] [Related]
15. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
[TBL] [Abstract][Full Text] [Related]
16. Long QT Syndrome Leading to Multiple Cardiac Arrests After Posaconazole Administration in an Immune-Compromised Patient with Sepsis: An Unusual Case Report.
Panos G; Velissaris D; Karamouzos V; Matzaroglou C; Tylianakis M
Am J Case Rep; 2016 Apr; 17():295-300. PubMed ID: 27125217
[TBL] [Abstract][Full Text] [Related]
17. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.
Ikeda Y; Umemura K; Kondo K; Sekiguchi K; Miyoshi S; Nakashima M
Clin Pharmacol Ther; 2004 Jun; 75(6):587-8. PubMed ID: 15179414
[No Abstract] [Full Text] [Related]
19. Voriconazole therapeutic drug monitoring: focus on safety.
Pasqualotto AC; Xavier MO; Andreolla HF; Linden R
Expert Opin Drug Saf; 2010 Jan; 9(1):125-37. PubMed ID: 20021293
[TBL] [Abstract][Full Text] [Related]
20. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms.
Levin MD; den Hollander JG; van der Holt B; Rijnders BJ; van Vliet M; Sonneveld P; van Schaik RH
J Antimicrob Chemother; 2007 Nov; 60(5):1104-7. PubMed ID: 17827141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
